Gastric-Esophageal Cancer

2 clinical trials · Condition

Record	Firm	Date
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (NCT05005403)	AbbVie	2021-11-01

Every clearance here is in the API, with alerts when new ones post.